Should you buy Arrowhead Pharmaceuticals stock now?
No, the technical signal for Arrowhead Pharmaceuticals is currently Strong Sell. Arrowhead Pharmaceuticals trades at $60.49 as of Oct 30, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -2.796 with rising momentum (signal: -3.706); RSI is at 42.6 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $107.71 points to 78.1% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Arrowhead Pharmaceuticals stock?
The average analyst price target for Arrowhead Pharmaceuticals is $107.71. The current price is $60.49, which gives an upside of 78.1%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $96.94 and $118.48.
Is Arrowhead Pharmaceuticals a dividend stock?
No, Arrowhead Pharmaceuticals does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals is rated as a stock in the risk category Unknown. Detailed risk data is currently not available.
Is Arrowhead Pharmaceuticals overvalued?
No, Arrowhead Pharmaceuticals is considered undervalued based on the analyst price target (78.1% upside). Arrowhead Pharmaceuticals has the following valuation ratios: a P/S ratio of 12.7, a P/B ratio of 17.9. The analyst price target suggests that the stock is undervalued by 78.1%.
Is Arrowhead Pharmaceuticals overbought?
No, Arrowhead Pharmaceuticals is not overbought. RSI is at 42.6 (neutral zone). The technical indicators show: RSI is at 42.6 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 1.3% above the 20-day average (short-term uptrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Arrowhead Pharmaceuticals earnings report?
Arrowhead Pharmaceuticals reports its next earnings on November 24, 2026. The stock currently trades at $60.49.
Is Arrowhead Pharmaceuticals shorted?
Yes, Arrowhead Pharmaceuticals is shorted with 10.8% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Arrowhead Pharmaceuticals stock?
No, insiders are not buying Arrowhead Pharmaceuticals shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 2 sales. On a net basis, 1,186,600 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 20,280,490 $ sold. Active sellers include PERRY MICHAEL S, OLUKOTUN ADEOYE Y, Lu Hongbo and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Arrowhead Pharmaceuticals a good stock?
Based on our total score, Arrowhead Pharmaceuticals is rated as a disastrous stock with a total score of 12 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 5/100, Quality: 7/100, Momentum: 26/100. In addition: analysts see 78.1% upside to the price target. Whether now is the time to buy is a separate question: the technical signal is Strong Sell. Whether Arrowhead Pharmaceuticals is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Arrowhead Pharmaceuticals stock?
The outlook for Arrowhead Pharmaceuticals based on current data: the average analyst price target is $107.71 (+78.1%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on Nov 24, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Arrowhead Pharmaceuticals stock moving?
Arrowhead Pharmaceuticals is stable right now. The technical indicators show: the price is close to the 20-day average; short interest is 10.8% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Arrowhead Pharmaceuticals go?
The average analyst price target for Arrowhead Pharmaceuticals is $107.71, which corresponds to a potential gain of 78.1% from the current price of $60.49. The stock has traded between $37.06 and $95.49 over the last 52 weeks. The price is 36.7% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Arrowhead Pharmaceuticals fall?
The stock has traded as low as $37.06 over the last 52 weeks — that is 38.7% below the current price of $60.49. The biggest decline (drawdown) in the same period was 61.2% from high to low. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Arrowhead Pharmaceuticals do?
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Arrowhead Pharmaceuticals as an investment.
Did Arrowhead Pharmaceuticals raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Arrowhead Pharmaceuticals. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Arrowhead Pharmaceuticals making money or losing money?
No, Arrowhead Pharmaceuticals is currently not making money — the company is losing money with a negative profit margin of -47.8%, a substantial loss. That means the business loses money on every dollar of revenue. The operating margin (profit before interest and taxes) is also negative at -226.0% — so it is not just financing costs weighing on the result. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Arrowhead Pharmaceuticals go bankrupt?
The bankruptcy risk of Arrowhead Pharmaceuticals is rated as moderate. Altman Z2 (a model for assessing financial distress) is 1.13 — that places the company in the middle zone. The Piotroski score (financial health 0-9, higher is better) is 4 — which is average. Debt relative to equity is 512% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Arrowhead Pharmaceuticals have a lot of debt?
Yes, Arrowhead Pharmaceuticals has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 512%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
